Clinical Trial Search

Primary: Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM) — 31 Participants

Primary: Proportion of Participants Who Responded to Treatment at 16 Weeks According to Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or…

Primary: Average Postoperative Pain Score - PACU/ Post-anesthesia Care Unit — 3.22; 5.66; 5.05 Pain score NSR

Primary: P2Y12 Reaction Units (PRU) — 47; 136; 39 PRU

Primary: Number of Participants Reporting Any Solicited Administration Site Adverse Event — 44 Participants

Primary: Change From Baseline in Domain 3 (Fluctuation-related Pain) of KING's PARKINSON's DISEASE PAIN SCALE (KPPS) — 17.2; 16.7; 17.1; 16.9 score on a scale

Primary: Antimicrobial Resistance (AMR) of Conjunctiva at 1 Week — 0; 0; 0 reads per million reads — p=1

Primary: Number of Participants That Received YESCARTA — 20 Participants

Primary: Visual Analog Scale (VAS) Pain Scores — 4.5; 5; 1; 1 score on a scale

Primary: Clinical Activity Score (a Composite Measure of Ophthalmological Signs and Symptoms) — 4.25; 2.77; 4.25; 4.20 score on a scale

Primary: PTSD Symptoms — 39.3; 38.6; 40.5 units on a scale

Primary: Time to Treatment Failure — NA; 119 Time to treatment failure (days) — p=<0.0001

Primary: Plasma Concentration Troponin I — 1.2; 1.2 ng/L — p=0.05

Primary: Change From Baseline in Untrimmed Total Mucus Volume at TLC — -0.1279; -0.1822; -0.0056; -0.1619 Milliliters (mL) — p=0.0327

Primary: Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment — 44.46156; 68.74241 mRNA units — p=<0.0001